In June 2011, Senior Scientific Inc was acquired by Manhatten Scientific (OTCQB:MHTX) - a firm focused on technology transfer and commercialization of transformative technologies in the nano medicine space withfacilites in New Mexico, New York and Montreal. Having expertise in nanotechnology and the physics of magnetic fields, along with the medical application of these fields, Senior Scientific focused on the rapidly emerging field of nanobiotechnology, with an emphasis on the early detection and localization of cancer and other human diseases. The firms technologies also held promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention. This technology, called Nanomagnetic relaxometry, relies upon the ability to detect tiny magnetic particles through the measurement of the magnetic fields they release after they are magnetized. Using specialized superparamagnetic nanoparticles with biocompatible coatings linked to specific antibodies, the firm is able to determine whether these particles are bound to their specific targets using the large difference between the relaxation times of bound and unbound particles. Because low frequency magnetic fields travel freely through human and animal tissue, Senior Scientific is able to measure these events both inside the body (in-vivo) and in tissue samples (ex-vivo). Preclinical research projects using this technique have focused on the early detection of breast cancer, ovarian cancer, leukemia, and Alzheimer's disease and non-invasive detection of transplant rejection. In 2016, it was announced that as the cancer diagnostic unit of Manhatten Scientific, Senior Scientifc would initsown right pursue an IPO and listing on the Australian Stock Exchange (ASX) and also changed the Senior Scientifc's name to Imagion Biosystems Inc.
